AKT1 and steatosis: Finally, the involvement of ANGPTL8 in lipid and glucose metabolism renders it as potential therapeutic/drug target in the context of steatosis/steatohepatitis, since, via the PI3K/Akt signaling pathway, ANGPTL8 enhances insulin sensitivity and promotes glycogen synthesis, while it inhibits gluconeogenesis (59, 60).